Press release
Gilead Sciences expands operations in Ireland with €7 million investment and creation of 140 new jobs
From Department of Enterprise, Trade and Employment
Published on
Last updated on
From Department of Enterprise, Trade and Employment
Published on
Last updated on
Gilead Sciences, Inc. (Nasdaq: GILD) today announced plans to invest approximately €7 million in the company’s Irish operations, opening a new base in Dublin and creating 140 jobs. As part of this expansion, the company will also establish a paediatric centre of excellence in Ireland.
Gilead’s manufacturing operations in Ireland supply countries across Europe and other parts of the world outside of the United States. The company has commenced the recruitment process and expects the positions to be filled by early 2022. Gilead is adding positions at all levels in departments including clinical development, process development and analytical operations, legal, human resources, supply chain, information technology, facilities and engineering, and financial shared services.
The company is currently in the process of selecting a location for its new Dublin office, where the majority of the new positions will be based with the remaining roles located at Gilead’s existing Cork facilities. Gilead expects to fill 80 of the positions over the coming 12 months, with the remainder hired by early 2022.
Today’s announcement builds upon Gilead’s 20 years of successful operations in Ireland. Gilead has invested more than €225 million in Ireland and has continually expanded its presence in the country. Currently, the company has 370 full-time employees in Ireland and an additional 119 contingent workers.
Tánaiste and Minister for Enterprise, Trade and Employment, Leo Varadkar TD said:
"Gilead has been steadily growing its presence here over the last 20 years and today’s announcement underlines the company’s commitment to Ireland. This expansion shows that Ireland offers the right conditions – particularly our skilled and talented workforce – to allow companies like Gilead to grow their operations here. I wish them well in this next exciting chapter."
David Cadogan, Vice President, Manufacturing Operations and General Manager, Gilead Sciences Ireland commented:
"Gilead has a long record of operating in Ireland and our teams here have played a critical role in ensuring that patients in Europe and other parts of the world outside of the United States have access to our medicines. With this additional investment, we are looking forward to continuing this important work and growing our presence here in Ireland."
Gilead’s sites in Ireland include a drug product manufacturing and packing facility in Carrigtwohill Co. Cork that manufactures and packages 22 Gilead drug products. The facility manufactures HIV and HCV solid oral products, representing 25 percent of Gilead’s total solid oral drug production. The company also has a financial shared services centre in Little Island, Co. Cork, which supports Gilead affiliates in Europe, Middle East, Asia and South America and was established 11 years ago, and a distribution centre in Dublin that distributes to 90 markets worldwide.
IDA Ireland CEO Martin Shanahan said:
"This is really positive news from the pharmaceutical industry in Ireland. We are delighted that, off the back of an already successful operation in the country, Gilead has decided to invest further in Ireland, creating 140 new roles. It demonstrates a huge vote of confidence in Ireland and our strong value proposition. I wish Gilead continued success with their Irish operations and assure them of IDA Ireland’s continued support."
For additional information on the job vacancies, please visit our LinkedIn page www.linkedin.com/company/gilead-sciences/jobs.
ENDS
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
Since 1999, Gilead has been building a strong presence in Ireland when it acquired NeXstar. Initially the U.S. pharmaceutical company focused on testing, release and distribution for the EU market. The company has significantly expanded its operations in Ireland to include drug product manufacturing and packaging for Europe and other markets outside the United States, a financial shared service centre and distribution and commercial operations.
Gilead Sciences is currently recruiting for positions across all levels in the following areas: